Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 21, 2024 07:00 ET | Source: MiNK Therapeutics

MiNK Reports Fourth Quarter and Year-End 2023 Results

Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with Immunoscape for development of...
March 07, 2024 07:30 ET | Source: MiNK Therapeutics

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
March 06, 2024 08:30 ET | Source: MiNK Therapeutics

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
February 14, 2024 08:00 ET | Source: MiNK Therapeutics

First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab

Dr. Yelena Janjigian, Chief of GI Cancers, Leads Investigator Sponsored Study at Memorial Sloan Kettering Cancer CenterTrial is Supported by Stand Up To Cancer as Part of an Initiative to Find...
February 06, 2024 08:00 ET | Source: MiNK Therapeutics

MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
January 30, 2024 08:00 ET | Source: MiNK Therapeutics

MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
December 20, 2023 07:30 ET | Source: MiNK Therapeutics

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

MiNK Therapeutics combines its unique, proprietary library of T-cell antigens with ImmunoScape’s cutting-edge platform for rapid discovery of novel T-cell receptors Therapeutic development to focus on...
November 09, 2023 07:00 ET | Source: MiNK Therapeutics

MiNK Therapeutics Reports Third Quarter 2023 Results

MiNK presents first-of-a-kind data with allogeneic iNKTs, agenT-797, showing durable clinical benefit in solid tumor cancers and persistence >6 months without toxic pre-conditioning.AgenT-797...
November 03, 2023 12:00 ET | Source: MiNK Therapeutics

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Clinical responses and durable activity with agenT-797 monotherapy and in combination with anti-PD-1First-of-a-kind persistence for an allogeneic cell therapy, with agenT-797 detected for up to 6...
October 30, 2023 08:00 ET | Source: MiNK Therapeutics

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...